Cardiacys Division · Phorcys Pharmaceuticals

Empaphor
SGLT-2 Inhibitor Range

Empagliflozin-based formulations for cardio-diabetic management

A novel SGLT-2 inhibitor with cardio-protective benefit

For patients with established CV disease and Type 2 diabetes. Three categories, five targeted formulations.

View Products Contact Our Team
Clinical Rationale

Type 2 Diabetes + These Risk Factors = Cardiovascular Risk

🫀

Hypertension & Abnormal Cholesterol

⚖️

Obesity & High Triglycerides

🏃

Lack of Physical Activity

🩸

Poorly Controlled Blood Sugar

🚬

Smoking

Managing these risk factors may avoid or delay the development of Cardiovascular Disease.
Ref: heart.org — Cardiovascular Disease & Diabetes
Product Range

The Empaphor Family

Three therapeutic categories — five targeted formulations for comprehensive Type 2 Diabetes management

Empagliflozin Monotherapy

Empagliflozin alone — for T2DM, Heart Failure & CKD

SGLT-2 Inhibitor
View Details →

Empagliflozin + Metformin

Fixed-dose combination — dual glycaemic action

Combination Therapy
View Details →

Empagliflozin + Linagliptin

Best of both — SGLT-2 + DPP-4 inhibition combined

Advanced Combination
View Details →
Clinical Evidence

Empagliflozin Significantly Improves Glycaemic Control

In pivotal clinical trials, Empagliflozin added to Metformin or Metformin + Sulfonylurea demonstrated statistically significant HbA1c reduction at 24 weeks (P<0.001).

−0.70%
HbA1c reduction vs Metformin monotherapy
−0.82%
HbA1c reduction vs Metformin + SU
P<0.001
Statistical significance in both arms
24 wk
Pivotal trial evaluation period
% Change in HbA1c at 24 Weeks vs Baseline
Empagliflozin vs Placebo
Placebo
−0.70%
vs Metformin
N=207 / N=217
Placebo
−0.82%
vs Met+SU
N=225 / N=225
Placebo
Empagliflozin
*P<0.001

Ref: Diabetes Care 2014;37:1650–1659 | Diabetes Care 2013;36:3396–3404

About Empaphor

Cardiacys Division
of Phorcys Pharmaceuticals

Empaphor is a brand of Phorcys Pharmaceuticals Pvt Ltd's Cardiacys Division — a dedicated cardio-diabetic division committed to bringing evidence-based solutions for cardiometabolic diseases to the Indian market.

Our product line focuses on Empagliflozin-based formulations, offering physicians a complete toolkit from initiation to intensification in Type 2 Diabetes management.

Learn more about Empaphor →

Full contact page →

Contact Us
🏢

Corporate Office

Door No. 4/502, Gaurav Excellency
Hatkesh Udyog Nagar, Mira Road East
Mumbai – 401107

🌐

Website

www.phorcyspharma.com

✉️

Email

info@phorcyspharma.com
phorcyspharma@gmail.com

For Healthcare Professionals Only. Empaphor is a prescription medicine. Please refer to the full prescribing information before recommending. Clinical data referenced from published literature as cited.